surmount-1 trial tirzepatide weight loss results Lilly orforglipron oral GLP-1 phase 3 SURPASS to SURMOUNT: The Tirzepatide

A 2023 clinical review found that unintended semaglutide overdoses resulted in hospitalization in 8% of cases, most involving severe gastrointestinal distress or hypoglycemia

Before approval, the FDA necessitated strong evidence that tirzepatide did not lead to an unacceptable risk of such serious side effects

When the CYP3A4 inducer is discontinued, the dose of SEROQUEL should be reduced to the original level within 7-14 days [see Clinical Pharmacology (12.3) and Drug Interactions (7.1)]

Patient Population The majority of patients who can tolerate semaglutide would be expected to have at least some weight loss from taking the drug, and according to the clinical expert, patients who report significant hunger and difficulty reducing portion sizes tend to be the patients who respond the most to the drug, although some weight loss is also seen in patients who do not report significant hunger or overeating

If the patient has stupor, coma, intestinal ileus, or protracted vomiting, she should be taken to the emergency department for further evaluation